No Data
Xiangyu Medical Report for the Third Quarter of 2024
Shanghai Xiangyu Medical (688626.SH): The net income in the first three quarters was 73.4139 million yuan, a year-on-year decrease of 59.02%.
Health Times October 29th丨Xiangyu Medical (688626.SH) announced that in the first three quarters of 2024, revenue reached 0.507 billion yuan, a decrease of 6.50% year-on-year; net income attributable to shareholders of the listed company was 73.4139 million yuan, a decrease of 59.02% year-on-year; basic earnings per share was 0.47 yuan.
Xiangyu Medical (688626.SH): has an early layout in the brain-computer interface field, currently mainly focusing on non-invasive methods.
Galonnay, October 22nd | Xiangyu Medical (688626.SH) stated on the interactive platform that the company has an early layout in the field of brain-computer interface, still mainly non-invasive at present. The company has applied for numerous patents, and some patents have been authorized. Various work is progressing in an orderly manner: 1. Products: brainwave acquisition device targeting newborn brain monitoring, brain attention issues, anxiety, depression, and emotional control, forming a comprehensive solution for brain function diagnosis and treatment. The product has entered the registration testing stage, and it is expected to start gradually obtaining certification in the first half of next year; 2. Independent technology and talent: Introducing well-known domestic experts in the field of mental health, and attract
Market Still Lacking Some Conviction On Xiangyu Medical Co.,Ltd (SHSE:688626)
Xiangyu Medical (688626.SH): Suzhou Jifeng, Jiaxing Jifeng No. 1, and Fuzhou Jifeng all did not reduce their shareholding in the company.
On September 10th, Gelonghui announced that Xiangyu Medical (688626.SH) received a notice on the expiration of the shareholding reduction plan and the results of the reduction from its shareholders, Suzhou Jifeng, Jiaxing Jifeng No.1, and Fuzhou Jifeng. As of September 10th, 2024, Suzhou Jifeng, Jiaxing Jifeng No.1, and Fuzhou Jifeng have not reduced their shareholding in the company. The shareholding reduction plan has come to an end upon its expiration.
Xiangyu Medical 2024 Semi-Annual Report
Investors Aren't Buying Xiangyu Medical Co.,Ltd's (SHSE:688626) EarningsNo Data
No Data
